Kornimate/medical-research-clean huggingface dataset:
liver transplantation for non-resectable colorectal liver metastasis

Conditions: Liver Metastasis Colon Cancer; Colorectal Cancer

Summary: the study aims to evaluate the efficacy of liver transplantation in the context of non-resectable colorectal liver metastasis. the primary endpoint is the overall survival in this group of patients while the secondary endpoint is the disease-free survival. patients included in this protocol will be evaluated either for whole or partial liver transplantation from deceased or living donors. type of different transplantations proposed are as follows: 1. whole liver graft or partial liver (split) from a deceased donor 2. partial liver graft retrieved from a deceased donor and orthotopically implanted after having performed a left hepatectomy in the recipient. 3. partial liver graft retrieved from a deceased donor and heterotopically implanted if total hepatectomy can not be performed. 4. partial liver graft retrieved from a living donor and orthotopically implanted after having performed total hepatectomy. 5. partial liver graft retrieved from a living donor and orthotopically implanted after having after having performed a left hepatectomy in the recipient. 6. partial liver graft retrieved from a living donor and heterotopically implanted if total hepatectomy can not be performed. in cases 2-3-5-6 total hepatectomy of native liver can be secondarily performed after having achieved a proper graft hypertrophy in order to avoid a small for size syndrome


Eligibility criteria:
inclusion criteria: * primary tumor resected according to standard oncological practice, p≤t4a, r0 resection * colorectal liver metastasis considered as non-resectable either up-front or after previous hepatic resections * no local recurrence of primary colon cancer confirmed by positron emission tomography, computed tomography and colonoscopy * no extra-hepatic metastatic disease confirmed by positron emission tomography and computed tomography * good performance status eastern cooperative oncology group 0 or 1 * neutrophils \> 1.000 * patients who received at least one line of chemotherapy for at least 3 months with partial response or stable disease according to modified response evaluation criteria in solid tumours * carcino-embryonic antigen \< 80 µg/l or reduction of ≥ 50% of highest carcino-embryonic antigen level observed * written informed consent * no other contraindications to liver transplantation exclusion criteria: * presence of other malignancies * local recurrence of primary tumor * extra-hepatic metastatic disease * patients who did not receive any neoadjuvant or adjuvant therapy * palliative resection of primary tumor * any other reason, according to the investigators, that could be a contraindication to protocol enrollment

Keywords: liver transplantation non-resectable colorectal liver metastasis
left atrial appendage occlusion in patients with non-valvular atrial fibrillation from shanghai

Conditions: Atrial Fibrillation; Left Atrial Appendage Occlusion

Summary: the prognostic implication of left atrial appendage occlusion (laao) procedure in non-valvular atrial fibrillation (nvaf) patients from china is still unclear. we aim to investigate the impact of laao procedure on subsequent clinical outcomes in patients from china.

although the left atrial appendage occlusion (laao) procedure has increasingly been performed to prevent the occurrence of ischemic stroke events among patients with non-valvular atrial fibrillation (nvaf), the clinical benefits and prognostic implications of which have not been well characterized in patients from china. as a result, we aim to conduct an observational study to explore the prognostic impact of laao in patient with nvaf who are hospitalized in shanghai tenth people's hospital.

Eligibility criteria:
inclusion criteria: * patients who were admitted for nvaf undergoing laao procedure between january 2014 and december 2017 in the cardiology department of shanghai tenth people's hospital; * adult patients (\>18 years old). exclusion criteria: * patients with rheumatic valvular disease; * patients with sick sinus syndrome; * patients who had a history of cardiac surgery (i.e., cabg); * patients who had received the catheter radiofrequency ablation procedure.

Keywords: atrial fibrillation; left atrial appendage occlusion
clinical study on a novel anti-adhesion barrier film

Conditions: Intrauterine Adhesion

Summary: the aim of this clinical study was to verify the effectiveness and safety of the anti-adhesion diaphragm in preventing intrauterine adhesions.

the main questions it aims to answer are * the efficacy of the anti-adhesion diaphragm in preventing intrauterine adhesions; * the duration of placement of the anti-adhesion septum in the uterus. participants will be asked to place an anti-adhesion diaphragm in the uterus for 3-7 days after the abortion procedure. the control group will receive conventional treatment with no other interventions. the researchers will compare the two groups to see if it is effective in clinical practice.

Eligibility criteria:
inclusion criteria: * voluntarily participate in this trial and sign a written informed consent; * women aged 18 ≤ age ≤ 40 years; * those who had an abortion in early pregnancy, and those who had a cleanse. exclusion criteria: * patients with scars; * patients with allergies; * patients with acute genitourinary tract infections; * patients with abnormalities of reproductive organs and abnormal uterine flexion after cesarean section; * patients with decreased menstrual flow after previous curettage; * patients with previous suspected or diagnosed uterine adhesions; * patients on immunosuppressive drugs; * patients with long-term use of antibiotics; * patients with malignant tumors of the reproductive organs; * patients with uterine adenomyosis, endometriosis, and uterine fibroids; * patients with severe systemic diseases; * patients with other conditions that are not suitable.

Keywords: induced abortion iua anti-adhesion barrier film
norris orien total cancer care

Conditions: Cancer Risk; Malignant Neoplasm

Summary: this research trial collects biological samples and clinical information to create a repository of data from patients with cancer or a predisposition for cancer. combining genetic information from biological samples and clinical data may lead to more knowledge about why certain cancers respond to treatment and help create more personalized medicine.

primary objectives: i. to establish a longitudinal study of clinical and related data from patients with or at risk for cancer. ii. to establish a large biospecimen repository that is linked to clinical and related data. iii. to follow patients through their lifetime though passive or active follow-up. iv. to use clinical data, tissues, other biological samples and derived molecular data in the total cancer care protocol (tccp) repositories to match patients in this tccp study to future studies. outline: patients undergo collection of blood during a regular care visit or not up to 4 times a year. extra tissue is collected after removal during standard of care surgery and patients may undergo additional tumor sampling (needle passes) at the time of planned diagnostic biopsies. during bone marrow biopsy, the doctor may reposition the needle up to 3 times, and bone marrow for research will not be collected more than 4 times per year. patients may undergo additional collection of other biological samples such as saliva, sputum, urine, feces, hair, and surface skin swabs for analysis. patients also receive surveys or questionnaires to collect demographics, medical, family, and nutritional history, cancer predisposing risk factors, quality of life data, and quality of care data. after completion of study, patients are followed up periodically.

Eligibility criteria:
inclusion criteria: * limited to those patients who are registered for outpatient or inpatient care at university of southern california (usc) norris * able to understand and sign the tccp informed consent, california subject's bill of rights, health insurance portability and accountability act (hipaa), and research authorization form directly or through an authorized representative; the informed consent, subject's bill of rights, hipaa, and research authorization will be available in both english and spanish languages exclusion criteria: * individuals who are not registered as patients for outpatient or inpatient care at usc norris * individuals who are unable to understand or sign the tccp informed consent, subject's bill of rights, hipaa, and research authorization in either english or spanish
systane® family - meibomian deficiency

Conditions: Dry Eye Syndrome

Summary: the purpose of this study was to assess the efficacy of the systane® family of products (systane® lid wipes, systane® balance lubricant eye drops, and systane® vitamins) on meibomian gland functionality in subjects with lipid deficiency related to evaporative dry eye as compared to the standard of care warm compresses.


Eligibility criteria:
inclusion criteria: * must have a clinical diagnosis of lipid deficient evaporative dry eye; * meibomian gland functionality - not more than 6 glands yielding liquid secretion; * must be willing to discontinue the use of all other meibomian gland; dysfunction management prior to receiving the study test article at visit 1, up until the end of the study period; * must have best corrected visual acuity of 20/40 snellen or better in each eye; * must be able to follow instructions and be willing and able to attend required study visits; * must read, sign, and date an ethics committee reviewed and approved informed consent form; * other protocol-defined inclusion criteria may apply. exclusion criteria: * history or evidence of ocular or intraocular surgery or serious ocular trauma in either eye within the past 6 months; * current punctal occlusion of any type (e.g., collagen plugs, silicone plugs); * history of intolerance or hypersensitivity to any component of the study medications; * history or evidence of epithelial herpes simplex keratitis (dendritic keratitis); vaccinia; active or recent varicella viral disease of the cornea and/or conjunctiva; chronic bacterial disease of the cornea and/or conjunctiva and/or eyelids; mycobacterial infection of the eye; and/or fungal disease of the eye; * pregnant or lactating at the time of enrollment; * not willing to take adequate precautions not to become pregnant during the study; * use of any concomitant topical ocular medications during the study period; * use of systemic medications that may contribute to dry eye unless on a stable dosing regimen for a minimum of 30 days prior to visit 1; * ocular conditions that may preclude the safe administration of either drop under investigation; * unwilling to discontinue contact lens wear during the study period and for at least 1 week prior to visit 1; * participation in an investigational drug or device study within 30 days of entering this study; * other protocol-defined exclusion criteria may apply.

Keywords: dry eye lipid deficiency meibomian gland
3d mr versus 3d ct for glenohumeral arthritis

Conditions: Arthritis; Glenohumeral Osteoarthritis

Summary: this study aims to assess the efficacy of three-dimensional magnetic resonance (mr) compared to three-dimensional computed tomography (ct) imaging. this proposed study is a prospective, unrandomized, single-blinded, self-controlled, and single-armed diagnostic radiological evaluation study.


Eligibility criteria:
inclusion criteria: * patients suffering from glenohumeral oa; * radiographic evidence of severe glenoid erosion; * indication for tsa based on clinical exam; * patient is willing to participate by complying with pre-operative visit requirements; * patient is willing and able to review and sign a study informed consent form. exclusion criteria: * prior arthroplasty at the affected shoulder; * patients with inflammatory arthritis; * patients with post-capsulorrhaphy arthritis; * patients with post-traumatic arthritis; * patients with rotator cuff tear arthropathy; * patients exhibiting a lack of physical or mental ability to perform or comply with the study procedures; * patients who are pregnant; * patients with implanted medical devices that are contraindicated to exposure up to a 3.0-tesla magnetic field.
prophylactic use of maribavir for the prevention of cytomegalovirus (cmv) disease in stem cell transplant recipients

Conditions: Cytomegalovirus Infections

Summary: the purpose of this research study is to investigate whether or not maribavir is safe and effective for preventing cmv disease when taken by mouth for up to 12 weeks in patients who have had a stem cell transplant.

cytomegalovirus (cmv) infections remain a significant problem following various types of transplants that are associated with strong immunosuppressive therapy. maribavir is a new oral anti-cmv drug with a novel mechanism of action compared to currently available anti-cmv drugs. this study will test the safety and efficacy of maribavir for the prevention of cmv disease when given as prophylaxis for up to 12 weeks following allogeneic stem cell transplant.

Eligibility criteria:
inclusion criteria: * allogeneic stem cell transplant recipient * recipient or donor cmv seropositive * have transplant engraftment * able to swallow tablets exclusion criteria: * cmv organ disease * hiv infection * use of other anti-cmv therapy post-transplant

Keywords: prevention prophylaxis cytomegalovirus cmv allogeneic stem cell transplant sct
translation, cross-cultural adaptation, reliability, validity and responsiveness of short form 36 (sf-36) questionnaire in stroke survivors

Conditions: Patient Satisfaction

Summary: the type of the study is an observational study to test in stroke survivors. the main questions it aims to answer are 1. what is a burmese version, content validity, convergent validity, divergent validity, and reliability of sf-36 questionnaire in stroke survivors? 2. does the burmese version of sf-36 have the responsiveness in stroke survivors? participants will be interviewed the questionnaire by the research team.

cross-cultural adaptation of a subjective questionnaire is required for use in a different country, culture, and/or language. although the majority of questionnaires were created in english-speaking nations, researchers must nonetheless take into account non-native populations in health studies, particularly when their omission could result in a systematic bias in studies of health care usage (beaton et al., 2000). for the purpose of translating and culturally adapting, it is crucial to achieve equality between the target and original sources of the questionnaire. as it relates to the authors' perspective, the short form 36 (sf-36) has not yet been translated and cross-culturally adapted to be used in myanmar. as a result, the features of a burmese version's reliability and validity among individuals with a history of stroke have not been studied in the previous research work. in addition, the questionnaire should also be tested for its responsiveness to provide clinical meaningful for health care professions. therefore, the aim of this study is to develop a burmese version of the sf-36 (sf-36-burmese) according to translation and cross-cultural adaption guidelines and evaluate its reliability, validity, and responsiveness (i.e., the instrument's capacity to identify changes over time in the construct being assessed) and the minimum clinical important difference (mcid, ie., the smallest change in an outcome that a patient would perceive as clinically meaningful) among stroke survivors.

Eligibility criteria:
inclusion criteria: 1. age 18 years and above (coppers et al., 2021; soto-vidal et al., 2021; wayessa et al., 2023) 2. hemiplegia induced by both ischemic and hemorrhagic stroke at least 1 month duration (wayessa et al., 2023; vincent-onabajo, owolabi \& hamzat, 2014) 3. ability to understand the study and respond to questions (on the mini- mental state examination \> 23) (wongchaisuwan et al., 2005; muangpaisan et al., 2015) 4. stable medical conditions exclusion criteria: 1. other neurological diseases such as parkinson's disease, dementia, alzheimer's disease, peripheral neuropathy according to medical history and record 2. recurrent stroke 3. participants with dysphasia, intellectual impairments, traumatic head injury, and psychiatric diseases (wayessa et al., 2023) 3) participants who cannot understand burmese language
effect of gene polymorphisms on glp-1 receptor agonists response in patients with t2dm

Conditions: Type 2 Diabetes Mellitus

Summary: 1. this is an prospective study to evaluate the effect of gene polymorphisms on therapeutic responses to glucagon like peptide-1 receptor agonist (glp-1 ra) in patients with t2dm. 2. t2dm patients and healthy subjects were recruited to identify genotypes and detect the level of t2dm susceptibility genes expression levels in the plasma of healthy participants and t2dm patients. 3. this is a retrospective cohort study of patients with t2dm who were treated with exenatide twice daily as a part of their diabetes care for at least 12 months.

many guidelines recommend the preferential use of glp-1 ra after single drug or multiple oral hypoglycemic drugs and basic insulin therapy for poor glycemic control. however, the clinical responsiveness to glp-1 ra varies among patients with t2dm. it has been reported that genetic factors are the important reasons for individual variation in therapeutic response of antidiabetic drugs. at present, dozens of gene loci related to therapeutic response of antidiabetic drugs have been screened, which are of great clinical significance in guiding clinical individualized treatment, improving the efficacy and safety of drugs, and reducing the drug costs. glp-1 ra was injected subcutaneously at standard dose and frequency for consecutive 6 months. the patients were visited at moths 0, 3, and 6, and medical histories, physical examinations, and routine clinical laboratory tests were performed during these visits. the general anthropometric parameters considered for this study were height (m), weight (kg), and waist and hip circumferences (cm) at baseline, 3 months and 6months after exenatide treatment. after an overnight fast, venous blood samples were obtained both in the fasting state and 2 h later during a standard 75-g oral glucose tolerance test. parameters were measured at baseline, the end of months 3 and 6 after administration of exenatide. peripheral blood was collected at follow-up and genomic dna was extracted from peripheral blood leucocytes. we further explored the association of gene polymorphisms with the therapeutic effect of glp-1 ra in patients with t2dm.

Eligibility criteria:
inclusion criteria: 1. a diagnosis of t2dm； 2. a body mass index (bmi) of 20-35 kg/m2； 3. an hba1c of 7.0%-12%, an age of 25-70 years； 4. required data available at baseline, 3 months, and 6 months after glp-1 ra therapy. exclusion criteria: 1. patients with serious diseases such as acute myocardial infarction, cerebral vascular accident, trauma, kidney or liver diseases, severe gastrointestinal dysfunction, and history of pancreatitis； 2. patients receiving glp-1 analogues, weight loss drugs, glucocorticoids, drugs affecting gastrointestinal peristalsis in the past 3 months； 3. those with missing data at the time points of baseline, 3 months, and 6 months after glp-1 ra therapy.

Keywords: t2dm glp-1 ra gene polymorphism
families defeating diabetes

Conditions: Diabetes Prevention

Summary: no evidence-based, evaluated, population-appropriate resources exist to translate type 2 diabetes (t2dm) primary prevention messages to canadians. significant barriers to such large-scale interventions include: * the need to identify, then target specific at-risk populations * significant time-delays before any program effects on t2dm incidence may manifest. however, women with gestational diabetes (gdm) are a readily identifiable study cohort at significant risk for recurrent gdm and t2dm-hence gdm women provide important opportunities for rigorous, timely diabetes prevention intervention studies. the investigators propose fdd (families defeating diabetes), a canadian diabetes prevention intervention uniquely targeting women with recent gdm in the context of their families. fdd is a 12 month, randomized, controlled t2dm prevention intervention targeting women with recent gdm, within their family context. five canadian sites and 177 women will participate. multifaceted information and behavioural change support will be provided for diet, weight loss, and activity through: seminar, walking groups, electronic updates, password-protected social networking site. subjects and controls will be compared for: dm prevention knowledge; diet/activity choices; hba1c; body habitus at study onset/during study/12 months/24 months. consenting immediate family members will have protective knowledge/diet/exercise choices/body habitus measures documented at study onset/12 and 24 months.


Eligibility criteria:
inclusion criteria: * women aged 18-50 with recent gdm * able to speak and write english * overweight (bmi \>25 before pregnancy) * significant other family members exclusion criteria: * women with types 1 or 2 diabetes * women with bmi under 25

Keywords: gestational diabetes gdm prevention
effects of aerobic exercise on basic metabolic panel perceived exertion and exercise adherence in elderly

Conditions: Obese; Elderly

Summary: participants were randomly assigned to two groups prior to their second visit: the high intensity interval training group a (hiit) and low intensity interval training group b (liit). the randomization processes were conducted in excel utilizing a random-number generator. prior to the second visit, each participants' target exercise heart rate ranges were determined. group a will receive a program of high intensity interval training program group b will receive a program of low intensity interval training program


Eligibility criteria:
inclusion criteria: * could stand and walk for 30m without becoming out of breath. * could walk safely without the aid of another person. * body mass index (bmi) ≥ 30 kg/m2 exclusion criteria: * uncontrolled preexisting health conditions such as: * uncontrolled hypertension * uncontrolled diabetes * uncontrolled heart disease
study to evaluate the safety and efficacy of relamorelin in participants with diabetic gastroparesis study 02

Conditions: Gastroparesis; Diabetes Mellitus

Summary: this study will evaluate the safety and efficacy of relamorelin compared to placebo in participants with diabetic gastroparesis. participants will report daily severity scores of their diabetic gastroparesis symptoms.


Eligibility criteria:
inclusion criteria: * diagnosis of type 1 or type 2 diabetes mellitus * meet the per protocol criteria of diabetic gastroparesis * compliance with diary * compliance with the per protocol study treatment dosing instructions exclusion criteria: * currently receiving nutrition intravenously, by nasogastric tube, or other feeding tube * actively experiencing anorexia nervosa, binge-eating, bulimia or other eating disorder at the time of screening (visit 1) * diagnosis of celiac disease, also a history of non-celiac gluten sensitivity * history of gastrointestinal disorders that may be similar to gastroparesis * functional dyspepsia diagnosed before the diagnosis of diabetes mellitus